Colleen Tetzlaf speaks to ecancer about what physician assistants need to know about PARP inhibitors in metastatic prostate cancer.
She starts by explaining what these drugs are and which patients benefit from these treatments. She talks about which PARP inhibitors are currently approved for prostate cancer.
Colleen concludes by discussing the benefits and risks of these drugs compared to other treatments for these patients.
This programme has been supported by an unrestricted educational grant from Pfizer.